Pharmaceutical Technology on MSN

Solve Therapeutics raises $120m as MSD joins list of backers

In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of ...
Pharmaceutical Technology on MSN

MSD bets big on flu antivirals with $9.2bn buyout of Cidara

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...
pharmaphorum

AHA: MSD's oral PCSK9 matches injectables

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...
pharmaphorum

Update: MSD's $9.2bn deal for flu biotech Cidara confirmed

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...
Pharmaceutical Technology on MSN

MSD secures $700m for broad-cancer ADC asset

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...
PharmaTimes

MSD’s oral cholesterol drug shows promise in late-stage trial

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...